Project Grant R01NS140319
Award Date 8/1/25
Completion Date 5/31/30
Dollars Obligated $612K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $559,030 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Medical University of South Carolina. The grant supports a 5-year research project to "Uncover the Signaling Mechanisms Underlying Treatment Failure in Medulloblastoma". The objective is to investigate the signaling pathways that enable certain progenitor cell populations to...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop novel small molecule inhibitors targeting the MBD2 protein for epigenetic therapy of medulloblastoma (MB), a common and aggressive pediatric brain cancer. The $564,045 award supports medicinal chemistry optimization of a lead compound, KCC07, which has shown promise in...
- This federal Project Grant award of $604,852.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to investigate the role of glial progenitor cells in the initiation and recurrence of medulloblastoma, the most common malignant childhood brain tumor. The research aims to advance the understanding of tumor heterogeneity,...
- This $443,354 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to investigate targeting the hexosamine biosynthetic pathway as a potential treatment for pediatric brain tumors. The research aims to understand how this metabolic pathway supports the growth and apoptosis resistance of diffuse midline gliomas with the...
- This federal Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to explore the mechanism of Notch inhibition resistance in glioblastoma (GBM) cancer stem-like cells. The goal is to develop novel therapies for this deadly brain cancer. The research project, led by the Regents of the University of Michigan, will identify GBM...
- This federal Project Grant award of $460,940 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research conducted by the University of Texas MD Anderson Cancer Center to investigate how genetic risk factors for glioma, a type of brain cancer, impact neurodevelopmental processes and potentially promote tumor formation. The research leverages human...
- This $559,587 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to examine the role of thyroid hormone in inhibiting the growth of medulloblastoma, the most common malignant brain tumor in children. The principal investigator at the Institute for Cancer Research, a non-profit research organization located in Pennsylvania, will investigate how thyroid hormone induces the differentiation of medulloblastoma tumor cells,...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $773,607 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Johns Hopkins University. The grant supports the development of brain-penetrant, histone evicting anthracycline drugs for the treatment of diffuse midline glioma (DMG), an aggressive and incurable form of pediatric brain cancer. The researchers are working to develop novel anthracycline...
- This federal Project Grant award of $109,076.00, awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) on December 17, 2025, supports research to immuno-modulate diffuse midline glioma, an aggressive pediatric brain tumor, through epigenetic reprogramming. The project, led by the University of Miami, aims to advance scientific understanding and develop new treatment approaches for this deadly disease. The 4-year project period runs through September 1, 2029. The...
- This $638,697 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research by the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM) to investigate the role of the SMARCA5 protein in the development and progression of glioblastoma, an aggressive type of brain cancer. The goal of the research is...